These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 34753031)

  • 1. Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis.
    Leonardi-Bee J; Boateng C; Faria R; Eliman K; Young B; Qureshi N
    Atherosclerosis; 2021 Dec; 338():7-14. PubMed ID: 34753031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis.
    Qureshi N; Woods B; Neves de Faria R; Saramago Goncalves P; Cox E; Leonardi Bee J; Condon L; Weng S; Akyea RK; Iyen B; Roderick P; Humphries SE; Rowlands W; Watson M; Haralambos K; Kenny R; Datta D; Miedzybrodzka Z; Byrne C; Kai J
    Health Technol Assess; 2023 Oct; 27(16):1-140. PubMed ID: 37924278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Family cascade screening for equitable identification of familial hypercholesterolemia: study protocol for a hybrid effectiveness-implementation type III randomized controlled trial.
    Johnson C; Chen J; McGowan MP; Tricou E; Card M; Pettit AR; Klaiman T; Rader DJ; Volpp KG; Beidas RS
    Implement Sci; 2024 Apr; 19(1):30. PubMed ID: 38594685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cascade testing of children and adolescents for elevated Lp(a) in pedigrees with familial hypercholesterolaemia.
    Loh WJ; Pang J; Chakraborty A; Ward NC; Chan DC; Hooper AJ; Bell DA; Burnett JR; Martin AC; Watts GF
    J Clin Lipidol; 2024; 18(1):e33-e37. PubMed ID: 38040538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing communication strategies and designing a comprehensive program to facilitate cascade testing for familial hypercholesterolemia.
    Campbell-Salome G; Jones LK; Walters NL; Morgan KM; Brangan A; Ladd IG; McGowan MP; Wilemon K; Schmidlen TJ; Simmons E; Schwartz MLB; McMinn MN; Tricou E; Rahm AK; Ahmed CD; Sturm AC
    BMC Health Serv Res; 2023 Apr; 23(1):340. PubMed ID: 37020233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review.
    Marquina C; Morton JI; Lloyd M; Abushanab D; Baek Y; Abebe T; Livori A; Dahal P; Watts GF; Ademi Z
    Pharmacoeconomics; 2024 Apr; 42(4):373-392. PubMed ID: 38265575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.
    Frey MK; Ahsan MD; Bergeron H; Lin J; Li X; Fowlkes RK; Narayan P; Nitecki R; Rauh-Hain JA; Moss HA; Baltich Nelson B; Thomas C; Christos PJ; Hamilton JG; Chapman-Davis E; Cantillo E; Holcomb K; Kurian AW; Lipkin S; Offit K; Sharaf RN
    J Clin Oncol; 2022 Dec; 40(35):4129-4143. PubMed ID: 35960887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceptability, Appropriateness, and Feasibility of Automated Screening Approaches and Family Communication Methods for Identification of Familial Hypercholesterolemia: Stakeholder Engagement Results from the IMPACT-FH Study.
    Jones LK; Walters N; Brangan A; Ahmed CD; Gatusky M; Campbell-Salome G; Ladd IG; Sheldon A; Gidding SS; McGowan MP; Rahm AK; Sturm AC
    J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34205662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cascade Screening in Familial Hypercholesterolemia: Achieving Buy-In and Turning Patients Into Partners.
    Khoury M
    CJC Pediatr Congenit Heart Dis; 2023 Oct; 2(5):219-221. PubMed ID: 37970215
    [No Abstract]   [Full Text] [Related]  

  • 10. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis.
    Marquina C; Lacaze P; Tiller J; Riaz M; Sturm AC; Nelson MR; Ference BA; Pang J; Watts GF; Nicholls SJ; Zoungas S; Liew D; McNeil J; Ademi Z
    Eur Heart J; 2022 Sep; 43(34):3243-3254. PubMed ID: 34788414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study.
    Sánchez-Ramos A; Fernández-Labandera C; Vallejo-Vaz AJ; Bonacho EC; Quevedo-Aguado L; Catalina-Romero C; Valdivielso P; Sánchez-Chaparro MÁ
    Atherosclerosis; 2021 Dec; 338():39-45. PubMed ID: 34785430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis.
    Di Costanzo A; Minicocci I; D'Erasmo L; Commodari D; Covino S; Bini S; Ghadiri A; Ceci F; Maranghi M; Catapano AL; Gazzotti M; Casula M; Montali A; Arca M
    J Clin Lipidol; 2021; 15(6):822-831. PubMed ID: 34756585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry.
    Roy G; Couture P; Genest J; Ruel I; Baass A; Bergeron J; Brisson D; Brunham LR; Cermakova L; Gaudet D; Khoury E; Laflamme N; Kennedy BA; Hegele RA; Drouin-Chartier JP
    Can J Cardiol; 2022 Mar; 38(3):311-319. PubMed ID: 34774719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia.
    Tromp TR; Cupido AJ; Reeskamp LF; Stroes ESG; Hovingh GK; Defesche JC; Schmidt AF; Zuurbier L
    Atherosclerosis; 2022 Jan; 340():61-67. PubMed ID: 34774301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel.
    Bjelakovic B; Stefanutti C; Reiner Ž; Watts GF; Moriarty P; Marais D; Widhalm K; Cohen H; Harada-Shiba M; Banach M
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttranscriptional Regulation of the Human LDL Receptor by the U2-Spliceosome.
    Zanoni P; Panteloglou G; Othman A; Haas JT; Meier R; Rimbert A; Futema M; Abou Khalil Y; Norrelykke SF; Rzepiela AJ; Stoma S; Stebler M; van Dijk F; Wijers M; Wolters JC; Dalila N; Huijkman NCA; Smit M; Gallo A; Carreau V; Philippi A; Rabès JP; Boileau C; Visentin M; Vonghia L; Weyler J; Francque S; Verrijken A; Verhaegen A; Van Gaal L; van der Graaf A; van Rosmalen BV; Robert J; Velagapudi S; Yalcinkaya M; Keel M; Radosavljevic S; Geier A; Tybjaerg-Hansen A; Varret M; Rohrer L; Humphries SE; Staels B; van de Sluis B; Kuivenhoven JA; von Eckardstein A
    Circ Res; 2022 Jan; 130(1):80-95. PubMed ID: 34809444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy.
    Krittanawong C; Khawaja M; Rosenson RS; Amos CI; Nambi V; Lavie CJ; Virani SS
    Curr Probl Cardiol; 2022 Jul; 47(7):101043. PubMed ID: 34780866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia.
    Ge X; Zhu T; Zeng H; Yu X; Li J; Xie S; Wan J; Yang H; Huang K; Zhang W
    Biomed Res Int; 2021; 2021():8032978. PubMed ID: 34754882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of a primary-tertiary shared care model to improve the detection of familial hypercholesterolaemia (FH): a mixed methods pre-post implementation study protocol.
    Birkenhead K; Sullivan D; Trumble C; Spinks C; Srinivasan S; Partington A; Elias L; Hespe CM; Fleming G; Li S; Calder M; Robertson E; Trent R; Sarkies MN
    BMJ Open; 2024 May; 14(5):e082699. PubMed ID: 38692720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National Experiences from 30 Years of Provider-Mediated Cascade Testing in Lynch Syndrome Families-The Danish Model.
    Lindberg LJ; Wadt KAW; Therkildsen C; Petersen HV
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.